Integrating Nephroprotective Therapies in Type 2 Diabetes: Clinical Guidance for the Diabetes Care Team

Abstract

Get full access to this article

View all access options for this article.

References

Adamczak

Kurnatowska

Naumnik

, et al. Pharmacological nephroprotection in chronic kidney disease patients with type 2 diabetes mellitus: clinical practice position statement of the Polish Society of Nephrology. Int J Mol Sci. 2024;25(23):12941. doi:10.3390/ijms252312941

Blazek

Bakris

GL.

Slowing the progression of diabetic kidney disease. Cells. 2023;12(15):1975. doi:10.3390/cells12151975

de Boer

Khunti

Sadusky

, et al. Diabetes management in chronic kidney disease: a consensus report by the ADA and KDIGO. Kidney Int. 2022;102(5):974-989. doi:10.1016/j.kint.2022.08.012

American Diabetes Association Professional Practice Committee. 11. Chronic kidney disease and risk management. Diabetes Care. 2025;48(suppl 1):S239-S251. doi:10.2337/dc25-S011

American Diabetes Association Professional Practice Committee. 9. Pharmacologic approaches to glycemic treatment. Diabetes Care. 2025;48(suppl 1):S181-S206. doi:10.2337/dc25-S009

Naaman

Bakris

GL.

Diabetic nephropathy: update on pillars of therapy slowing progression. Diabetes Care. 2023;46(9):1574-1586. doi:10.2337/dci23-0030

Chen

Knicely

Grams

ME.

Chronic kidney disease diagnosis and management: a review. JAMA. 2019;322(13):1294-1304. doi:10.1001/jama.2019.14745

Mark

Sarafidis

Ekart

, et al. SGLT2i for evidence-based cardiorenal protection in diabetic and non-diabetic CKD: review by EURECA-m and ERBP. Nephrol Dial Transplant. 2023;38(11):2444-2455. doi:10.1093/ndt/gfad112

Natale

Tunnicliffe

Toyama

, et al. SGLT2 inhibitors for people with CKD and diabetes. Cochrane Database Syst Rev. 2024;5:CD015588. doi:10.1002/14651858.CD015588.pub2

10.

Mavrakanas

Tsoukas

Brophy

, et al. SGLT2 inhibitors improve CV and renal outcomes in patients with CKD: systematic review and meta-analysis. Sci Rep. 2023;13(1):15922. doi:10.1038/s41598-023-42989-z

11.

Impact of diabetes on the effects of SGLT2 inhibitors on kidney outcomes: collaborative meta-analysis. Lancet. 2022;400(10365):1788-1801. doi:10.1016/S0140-6736(22)02074-8

12.

Georgianos

Vaios

Eleftheriadis

Papachristou

Liakopoulos

Therapeutic advances in diabetic kidney disease. Int J Mol Sci. 2023;24(3):2803. doi:10.3390/ijms24032803

13.

Yang

Lang

Yang

, et al. Efficacy and safety of drugs for T2DM and CKD on kidney and CV outcomes: systematic review and network meta-analysis. Diabetes Res Clin Pract. 2023;198:110592. doi:10.1016/j.diabres.2023.110592

14.

Solis-Herrera

Triplitt

Non-steroidal mineralocorticoid receptor antagonists in patients with chronic kidney disease and type 2 diabetes. Diabetes Obes Metab. 2024;26(2):417-430. doi:10.1111/dom.15327

15.

Agarwal

Green

Heerspink

HJL

, et al. Impact of simultaneous initiation of finerenone and empagliflozin on urinary albumin-to-creatinine ratio in Asia: pre-specified analysis of CONFIDENCE. Clin J Am Soc Nephrol. 2026;21(1):72-82. doi:10.2215/CJN.0000000865

16.

Stevens

Ahmed

Carrero

, et al. KDIGO 2024 Clinical Practice Guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024;105(4, suppl):S117-S314. doi:10.1016/j.kint.2023.10.018

17.

Amir

Kim

etal; CRIC Study Investigators. Adherence to plant-based diets and risk of CKD progression and all-cause mortality: findings from the Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis. 2024;83(5):624-635. doi:10.1053/j.ajkd.2023.09.020

18.

Centers for Medicare & Medicaid Services. Medical nutrition therapy services. Updated January 1, 2024. Accessed January 4, 2026. https://www.medicare.gov/coverage/medical-nutrition-therapy-services

19.

Czupryniak

Mosenzon

Rychlík

, et al. Barriers to early diagnosis of CKD and use of SGLT2 inhibitors: review and call to action. Diabetes Obes Metab. 2024;26(10):4165-4177. doi:10.1111/dom.15789

20.

Młynarska

Buławska

Czarnik

, et al. Novel insights into diabetic kidney disease. Int J Mol Sci. 2024;25(18):10222. doi:10.3390/ijms251810222